Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans

E. P. Bouras, D. D. Burton, Michael Camilleri, D. A. Stephens, G. M. Thomforde

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Endogenous prostaglandins regulate smooth muscle activity; prostaglandins and cyclooxygenase (COX) inhibitors influence gastrointestinal motility in inflammatory states such as postoperative ileus in animal models. The objective of this study was to evaluate the effects of two COX-2 inhibitors on gastric emptying and intestinal transit in healthy humans. In a double-blind, placebo-controlled, parallel-group study, 66 healthy volunteers were randomized to one of two commercially available oral COX-2 inhibitors (celecoxib and rofecoxib), cisapride (positive control), or placebo. Following 7 days on therapy, study participants underwent a test of gastric emptying and small bowel transit of liquids and solids using scintigraphy. Data were analysed using Kruskal-Wallis (ANOVA on ranks) and Mann-Whitney rank sum tests. There were significant group effects on transit of solids: gastric emptying (ANOVA, P = 0.005) and small bowel transit (ANOVA, P = 0.056). However, neither COX-2 inhibitor significantly accelerated the liquid or solid gastric emptying or small bowel transit compared with placebo. The positive control, cisapnde, accelerated gastric emptying of solids (post-lag slope of gastric emptying, P < 0.05), and small bowel transit of solids (t10%, P = 0.016). At maximum clinically approved dosages, celecoxib and rofecoxib have no significant effects on gastric emptying or small intestinal transit in healthy humans. Cisapride accelerates gastric emptying and small bowel transit in healthy humans.

Original languageEnglish (US)
Pages (from-to)729-735
Number of pages7
JournalNeurogastroenterology and Motility
Volume16
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

Cyclooxygenase 2 Inhibitors
Gastric Emptying
Celecoxib
Cisapride
Analysis of Variance
Placebos
Prostaglandin Antagonists
Gastrointestinal Motility
Cyclooxygenase Inhibitors
Ileus
Prostaglandin-Endoperoxide Synthases
Nonparametric Statistics
Radionuclide Imaging
Prostaglandins
Smooth Muscle
Healthy Volunteers
Animal Models

Keywords

  • Celecoxib
  • Cisapride
  • Cyclooxygenase-2 inhibitors
  • Gastric emptying
  • Gastrointestinal transit
  • Rofecoxib
  • Serotonergic agonist

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Neuroscience(all)

Cite this

Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. / Bouras, E. P.; Burton, D. D.; Camilleri, Michael; Stephens, D. A.; Thomforde, G. M.

In: Neurogastroenterology and Motility, Vol. 16, No. 6, 12.2004, p. 729-735.

Research output: Contribution to journalArticle

Bouras, E. P. ; Burton, D. D. ; Camilleri, Michael ; Stephens, D. A. ; Thomforde, G. M. / Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. In: Neurogastroenterology and Motility. 2004 ; Vol. 16, No. 6. pp. 729-735.
@article{19a9ec764e994c8795225df76ee58433,
title = "Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans",
abstract = "Endogenous prostaglandins regulate smooth muscle activity; prostaglandins and cyclooxygenase (COX) inhibitors influence gastrointestinal motility in inflammatory states such as postoperative ileus in animal models. The objective of this study was to evaluate the effects of two COX-2 inhibitors on gastric emptying and intestinal transit in healthy humans. In a double-blind, placebo-controlled, parallel-group study, 66 healthy volunteers were randomized to one of two commercially available oral COX-2 inhibitors (celecoxib and rofecoxib), cisapride (positive control), or placebo. Following 7 days on therapy, study participants underwent a test of gastric emptying and small bowel transit of liquids and solids using scintigraphy. Data were analysed using Kruskal-Wallis (ANOVA on ranks) and Mann-Whitney rank sum tests. There were significant group effects on transit of solids: gastric emptying (ANOVA, P = 0.005) and small bowel transit (ANOVA, P = 0.056). However, neither COX-2 inhibitor significantly accelerated the liquid or solid gastric emptying or small bowel transit compared with placebo. The positive control, cisapnde, accelerated gastric emptying of solids (post-lag slope of gastric emptying, P < 0.05), and small bowel transit of solids (t10{\%}, P = 0.016). At maximum clinically approved dosages, celecoxib and rofecoxib have no significant effects on gastric emptying or small intestinal transit in healthy humans. Cisapride accelerates gastric emptying and small bowel transit in healthy humans.",
keywords = "Celecoxib, Cisapride, Cyclooxygenase-2 inhibitors, Gastric emptying, Gastrointestinal transit, Rofecoxib, Serotonergic agonist",
author = "Bouras, {E. P.} and Burton, {D. D.} and Michael Camilleri and Stephens, {D. A.} and Thomforde, {G. M.}",
year = "2004",
month = "12",
doi = "10.1111/j.1365-2982.2004.00547.x",
language = "English (US)",
volume = "16",
pages = "729--735",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans

AU - Bouras, E. P.

AU - Burton, D. D.

AU - Camilleri, Michael

AU - Stephens, D. A.

AU - Thomforde, G. M.

PY - 2004/12

Y1 - 2004/12

N2 - Endogenous prostaglandins regulate smooth muscle activity; prostaglandins and cyclooxygenase (COX) inhibitors influence gastrointestinal motility in inflammatory states such as postoperative ileus in animal models. The objective of this study was to evaluate the effects of two COX-2 inhibitors on gastric emptying and intestinal transit in healthy humans. In a double-blind, placebo-controlled, parallel-group study, 66 healthy volunteers were randomized to one of two commercially available oral COX-2 inhibitors (celecoxib and rofecoxib), cisapride (positive control), or placebo. Following 7 days on therapy, study participants underwent a test of gastric emptying and small bowel transit of liquids and solids using scintigraphy. Data were analysed using Kruskal-Wallis (ANOVA on ranks) and Mann-Whitney rank sum tests. There were significant group effects on transit of solids: gastric emptying (ANOVA, P = 0.005) and small bowel transit (ANOVA, P = 0.056). However, neither COX-2 inhibitor significantly accelerated the liquid or solid gastric emptying or small bowel transit compared with placebo. The positive control, cisapnde, accelerated gastric emptying of solids (post-lag slope of gastric emptying, P < 0.05), and small bowel transit of solids (t10%, P = 0.016). At maximum clinically approved dosages, celecoxib and rofecoxib have no significant effects on gastric emptying or small intestinal transit in healthy humans. Cisapride accelerates gastric emptying and small bowel transit in healthy humans.

AB - Endogenous prostaglandins regulate smooth muscle activity; prostaglandins and cyclooxygenase (COX) inhibitors influence gastrointestinal motility in inflammatory states such as postoperative ileus in animal models. The objective of this study was to evaluate the effects of two COX-2 inhibitors on gastric emptying and intestinal transit in healthy humans. In a double-blind, placebo-controlled, parallel-group study, 66 healthy volunteers were randomized to one of two commercially available oral COX-2 inhibitors (celecoxib and rofecoxib), cisapride (positive control), or placebo. Following 7 days on therapy, study participants underwent a test of gastric emptying and small bowel transit of liquids and solids using scintigraphy. Data were analysed using Kruskal-Wallis (ANOVA on ranks) and Mann-Whitney rank sum tests. There were significant group effects on transit of solids: gastric emptying (ANOVA, P = 0.005) and small bowel transit (ANOVA, P = 0.056). However, neither COX-2 inhibitor significantly accelerated the liquid or solid gastric emptying or small bowel transit compared with placebo. The positive control, cisapnde, accelerated gastric emptying of solids (post-lag slope of gastric emptying, P < 0.05), and small bowel transit of solids (t10%, P = 0.016). At maximum clinically approved dosages, celecoxib and rofecoxib have no significant effects on gastric emptying or small intestinal transit in healthy humans. Cisapride accelerates gastric emptying and small bowel transit in healthy humans.

KW - Celecoxib

KW - Cisapride

KW - Cyclooxygenase-2 inhibitors

KW - Gastric emptying

KW - Gastrointestinal transit

KW - Rofecoxib

KW - Serotonergic agonist

UR - http://www.scopus.com/inward/record.url?scp=11144335481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144335481&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2004.00547.x

DO - 10.1111/j.1365-2982.2004.00547.x

M3 - Article

C2 - 15601422

AN - SCOPUS:11144335481

VL - 16

SP - 729

EP - 735

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 6

ER -